Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
Alterity Therapeutics Limited - American Depositary Shares (ATHE)
Company Research
Source: GlobeNewswire
Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February 2025ATH434-201 trial in early-stage MSA completed in November 2024Positive interim data presented at MDS from the ATH434-202 Phase 2 trial in advanced MSAMultiple data presentations and publications showing the potential for ATH434 to modify disease progression in neurodegenerative conditionsCash balance on 31 December 2024 of A$4.54 m MELBOURNE, Australia and SAN FRANCISCO, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenera
Read more
Impact Snapshot
Event Time:
ATHE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ATHE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ATHE alerts
High impacting Alterity Therapeutics Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ATHE
News
- Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System AtrophyGlobeNewswire
- Alterity Therapeutics Raises A$40.0 million in PlacementGlobeNewswire
- Alterity Therapeutics Limited (NASDAQ: ATHE) was downgraded by analysts at Benchmark Co. from a "speculative buy" rating to a "hold" rating.MarketBeat
- Alterity Therapeutics Limited (NASDAQ: ATHE) had its price target raised by analysts at Maxim Group from $8.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
- Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical EfficacyGlobeNewswire
ATHE
Sec Filings
- 3/27/25 - Form 6-K
- 3/25/25 - Form 6-K
- 3/14/25 - Form 6-K
- ATHE's page on the SEC website